Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The effect of adjuvants on the immune response induced by a DBL4ɛ-ID4 VAR2CSA based Plasmodium falciparum vaccine against placental malaria

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Impact analysis of rotavirus vaccination in various geographic regions in Western Europe

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Self-reported immunity and opinions on vaccination of hospital personnel among paediatric healthcare workers in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Are refugees arriving in Denmark an under-immunised group for measles? A cross-sectional serology study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Risk of COVID-19 in health-care workers in Denmark: an observational cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
A vaccine protecting women against placental malaria could be based on the sub-domains of the VAR2CSA antigen, since antibodies against the DBL4ɛ-ID4 subunit of the VAR2CSA protein can inhibit parasite binding to the placental ligand chondroitin sulphate A (CSA). Here we tested the ability of DBL4ɛ-ID4 to induce binding-inhibitory antibodies when formulated with adjuvants approved for human use. We have characterized the immune response of DBL4ɛ-ID4 in combination with Freund's complete and incomplete adjuvant and with three adjuvants currently being used in clinical trials: Montanide(®) ISA 720, Alhydrogel(®) and CAF01. Antibodies induced against DBL4ɛ-ID4 in combination with these adjuvants inhibited parasite binding to CSA from 82% to 99%. Although, different epitope recognition patterns were obtained for the different formulations, all adjuvant combinations induced strong Th1 and Th2 type responses, resulting in IgG with similar binding strength, with to the DBL4ɛ-ID4 antigen. These results demonstrate that the DBL4ɛ-ID4 antigen is highly immunogenic and that binding inhibitory antibodies are induced when formulated with any of the tested adjuvants.
Original languageEnglish
JournalVaccine
Volume30
Issue number3
Pages (from-to)572-9
Number of pages8
ISSN0264-410X
DOIs
Publication statusPublished - 2012

    Research areas

  • Adjuvants, Immunologic, Animals, Antibodies, Protozoan, Antigens, Protozoan, Cell Adhesion, Chondroitin Sulfates, Disease Models, Animal, Female, Malaria Vaccines, Malaria, Falciparum, Placenta Diseases, Pregnancy, Rats, Rats, Wistar

ID: 36494338